Secondary Neoplasms of the Urinary Bladder-Clinical Management and Oncological Outcomes by El-Taji, Omar et al.
  Transl Androl Urol 2021;10(6):2427-2434 | http://dx.doi.org/10.21037/tau-20-955© Translational Andrology and Urology. All rights reserved.
Original Article
Secondary neoplasms of the urinary bladder-clinical management 
and oncological outcomes
Omar El-Taji1^, Abdullah Al-Mitwalli1, Farhan Malik2, Samita Agarwal3, Andrew Gogbashian4,  
Rob Hughes5, Nikhil Vasdev1,6, Anand Sharma5
1Department of Urology, Lister Hospital, East and North Herts NHS Trust, Stevenage, SG1 4AB UK; 2Imperial College Business School, London, 
UK; 3Department of Histopathology, Lister Hospital, East and North Herts NHS Trust, Stevenage, SG1 4AB, UK; 4Department of Radiology, 
Mount Vernon Cancer Centre, Paul Strickland Scanner Centre, Northwood, HA6 2RN, UK; 5Department of Medical Oncology, Mount Vernon 
Cancer Centre, Northwood, HA6 2RN, UK; 6School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK
Contributions: (I) Conception and design: O El-Taji, A Sharma, N Vasdev; (II) Administrative support: A Al-Mitwalli; (III) Provision of study materials 
or patients: S Agarwal, R Hughes, A Gogbashia; (IV) Collection and assembly of data: O El-Taji, S Agarwal; (V) Data analysis and interpretation: O 
El-Taji, F Malik; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
Correspondence to: Mr. Omar El-Taji. Urology Registrar, Lister Hospital, East & North Hertfordshire NHS TrustCoreys Mill Lane Stevenage, SG1 
4AB, UK. Email: Omar.el-taji@nhs.net.
Background: Secondary neoplasms of the bladder account for 4.5% of all bladder neoplasms however 
there is limited literature reporting management and survival. This is the largest single centre series 
presented in current literature with long term oncological follow up. 
Methods: This is a single institutional, retrospective cohort study of patients with a histological diagnosis of 
a secondary bladder neoplasm from January 2007 to December 2017 (n=40). Prognostic variables examined 
included age at diagnosis, histology, disease free survival and treatment. Kaplan-Meier analysis was used to 
calculate survival. We used multiple regression analysis to identify the most significant treatments for each 
population group in terms of their survival. 
Results: Twenty-one patients were male (53%) with a median age of 68 and 19 were female (47%) with 
a median age of 64. The most common secondary neoplasms and their median survival were prostate [12 
patients (30%), 446 days], colorectal [9 patients (23%), 403 days], ovarian [5 patients (13%), 369 days], 
cervical [4 patients (10%), 148 days], breast [3 patients (8%), 241 days], lymphoma [3 patients (8%), 145 days],  
gastric [2 patients (5%), 66 days], and renal [2 patients (5%), 854 days]. Those receiving treatment following 
a secondary diagnosis demonstrated statistical significance in survival for colorectal (surgery P=0.013), 
prostate (radiotherapy P=0.0012 and hormonal therapy P=0.004) and ovarian cancer (chemotherapy 
P=0.00002). 
Conclusions: Prognosis and treatment depends upon the primary neoplasm. There is some survival 
benefit in well selected patients receiving treatment following a diagnosis of a bladder secondary.
Keywords: Bladder cancer; metastatic cancer; survival; secondary neoplasm
Submitted May 28, 2020. Accepted for publication Dec 23, 2020.
doi: 10.21037/tau-20-955




2428 El-Taji et al. Secondary neoplasms of the urinary bladder
  Transl Androl Urol 2021;10(6):2427-2434 | http://dx.doi.org/10.21037/tau-20-955© Translational Andrology and Urology. All rights reserved.
Introduction
The urinary bladder appears to be the second most 
common site to be involved in secondary neoplasms to the 
genitourinary tract following the kidney (1). This accounts 
for 4.5% of all bladder neoplasms, and is often misdiagnosed, 
due to lack of any symptoms, i.e., haematuria (2).
Secondary neoplasms to the urinary bladder can be a 
result of direct extension from another pelvic malignancy, 
metastasis  from distant organs,  or hematopoietic 
malignancies as part of more extensive disease (3). The 
majority of secondary bladder tumours come from direct 
spread, as demonstrated by Velcheti et al. and Morichetti 
et al. (4,5). A smaller proportion of secondary neoplasms 
of the bladder are secondary to metastatic deposits, most 
commonly the breast, stomach, lung and skin (6,7). In 
some circumstances the histological appearances may be 
characteristic but many secondary tumours, particularly 
adenocarcinomas, can pose diagnostic difficulty (8,9). There 
is limited literature available reporting, the management 
and survival of secondary neoplasms to the bladder and of 
those available these are early studies and/or of small series 
(10-12). Moreover the majority of published data has been 
from autopsy which gives us incomplete details of disease 
management. 
The available data suggests the most common primary 
sites of tumour origin that metastasise to the bladder are 
colon, prostate, rectum and cervix. These often reflect the 
most common histological subtype of each cancer origin 
(2,4-7,12). Breast cancer primaries metastasising to the 
bladder have the most data on management and survival 
however these studies vary on survival ranging from 1 month 
to over 5 years (10,13). While it has been reported that 
radiotherapy should be considered to provide local 
disease control, treatment often involves a combination 
of chemotherapy and hormonal treatment (especially in 
prostate and breast cancer) (14). Partial and complete 
cystectomy have been rarely reported (4). 
We aim to report our institution’s experience of 
secondary neoplasms of the bladder from various primary 
sites and the surgical and oncological management of these 
patients in addition to their survival. This is the largest 
single centre series presented in current literature with long 
term oncological follow up. We anticipate that this will help 
clinicians better understand the clinical presentation and 
management of patients with secondary neoplasms to the 
bladder.
We present the following article in accordance with the 




This is a single institutional, retrospective cohort study. The 
study was conducted in accordance with the Declaration of 
Helsinki (as revised in 2013). The study was approved by 
the institutional review board (Lister Hospital, #17149) and 
individual consent for this retrospective analysis was waived. 
We retrieved data from all patients who had secondary 
neoplasms to the bladder treated at our centre from January 
2007 to December 2017. We defined these as tumours 
involving the urinary bladder via direct spread from 
adjacent advanced tumours, or distant metastasis (including 
from hematopoietic malignancies). We ensured all patients 
had a diagnosis of secondary bladder neoplasm either by 
a histological appearance comparable to that of a primary 
tumour or that the histological features were incompatible 
with a urothelial origin. Furthermore the secondary tumour 
must have demonstrated invasion into the muscularis and/
or lamina propria. Excluded from our study were patients 
with primary atypical bladder cancer which included 
primary squamous cell carcinoma, primary adenocarcinoma, 
sarcomatoid carcinoma and neuroendocrine tumours. 
We identified 40 patients with a diagnosis of secondary 
tumour of the urinary bladder over a 10-year period. Fifty-
four cases were excluded from our study due to atypical 
histology. All cases were diagnosed by either transurethral 
resection of bladder tumour (TURBT) or bladder biopsy.
Measures and outcome assessments
Prognostic variables examined included age at diagnosis, 
sex, histology, clinical presentation, disease free survival 
and treatment. The treatments we examined included 
surgery, radiotherapy, chemotherapy and/or hormonal 
therapy prior to a diagnosis of secondary neoplasm as well 
as surgery, chemotherapy, radiotherapy and/or hormonal 
treatment following a diagnosis of secondary bladder 
neoplasm. Patient selection and variables were obtained 
through reviewing clinical history, histopathology, history 
of lymphovascular spread, radiological support of non-
bladder origin, and Immunohistochemical analysis. Kaplan-
Meier analysis was used to calculate survival. Our primary 
outcome measure was overall survival. Survival was defined 
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as number of days from secondary diagnosis of a bladder 
neoplasm to death or to our censorship date (19th May 
2019). We followed up all patients until the censorship date. 
Information bias was reduced by searching through both 
pathological and oncological data. 
Statistical analyses
Prism 6 (GraphPad Software, Inc., San Diego, CA) was 
used for graphical representation and statistical analysis. 
A two tailed t-test was used to determine the relationship 
amongst categorical variables. We used GRETL (Gnu 
Regression, Econometrics and Time-series Library 64bit) 
software to create a multiple regression analysis using step-
wise backwards elimination to build models which identified 
the most significant treatments for each population group 
in terms of their survival. We defined the optimal model 
as the one with P values lower than our significance 95% 
(P value <0.05). We estimated overall survival using the 
Kaplan-Meier method. All statistical tests were two-sided by 
default, and the significance level was set to 0.05 unadjusted 
for multiple comparisons. 
Results
We identified 40 patients with a diagnosis of secondary 
tumour of the urinary bladder. All 40 patients who 
were included in our study, completed follow-up, and 
were analysed. In the study population, average age at 
presentation was 68 (40–90) in men and 64 (48–80) years in 
women, with 50% of these patients having history of a non-
bladder primary malignancy (Table 1). The median survival 
of our patient cohort from diagnosis of a bladder secondary 
neoplasm was 272 days (Figure 1). Complete patient 
management as well as individual survival is detailed in the 
attached Appendix 1, individual tumour characteristics are 
mentioned below. 
There were 12 patients with secondary bladder 
neoplasms of prostatic origin with histological analysis 
demonstrating adenocarcinoma. The median age was 
74 (51–90) and 8 patients were diagnosed at cystoscopy 
for urinary symptoms, with 1 patient diagnosed at 
transurethral resection of prostate (TURP) performed for 
lower urinary tract symptoms with no previous history 
of malignancy. 3 patients had imaging suggestive of a 
bladder tumour and 4 patients had a previous history of 
prostate adenocarcinoma. The median time from primary 
to secondary diagnosis was 981 days (948–4,748 days). All 
specimens exhibited carcinoma infiltrating the muscularis 
propria. Immunohistochemistry analysis demonstrated 
positivity for PSA and PSAP confirming the prostatic 
origin of the specimen. AMACR 63 and CK5 favoured the 
diagnosis of prostatic adenocarcinoma. Of these patients 
5 (42%) continue on treatment for prostate cancer. The 
median survival for our patients was 446 days (Table 2). Our 
results show that fewer days from primary (prostate) to 
secondary (bladder) diagnosis (P=0.0013), patients receiving 
radiotherapy after diagnosis of a secondary bladder 
neoplasm (P=0.0012), and those receiving hormonal therapy 
after secondary diagnosis (P=0.004) had the most significant 
survival advantage. There was no significance in survival of 
those patients undergoing chemotherapy following their 
diagnosis (Table 3). 
A total of 9 patients with bladder metastases were from a 
colorectal primary with a median age of 62 (40–75) with the 
histological diagnosis of adenocarcinoma. One patient was 
Table 1 Patient demographics with those known to have history of a non-bladder primary malignancy
Male (n=21) Female (n=19)
Age at presentation 68 (40–90) 64 (48–80)


















Figure 1 Kaplan-Meier curve of overall survival for all 40 patients 
following diagnosis of a secondary neoplasm to the urinary bladder.
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diagnosed following cystoscopy for haematuria, 1 patient 
following an acute presentation with abdominal pain whilst 
the rest were diagnosed following suspicious radiological 
findings. Five patients had a known prior history of 
colorectal adenocarcinoma and 1 patient presented with a 
vesico-vaginal fistula. The median time from primary to 
secondary diagnosis was 531 days (62–2,979). All specimens 
exhibited carcinoma infiltrating the muscularis propria. 
Immunohistochemistry analysis demonstrated in the vast 
majority of cases, positivity for CK20, CK7 and CDX-
2. K-Ras sequencing results were available for 2 patients, 
both of which demonstrated a mutated gene. The median 
survival for our patients was 403 days (Table 2). Our results 
show patients undergoing surgery at initial diagnosis 
(P=0.03) and following diagnosis of a bladder secondary 
(P=0.013) had a survival advantage. Moreover, patients 
who received radiotherapy following diagnosis of a bladder 
secondary had an improved survival (P=0.045). Days from 
primary to secondary diagnosis as well as patients receiving 
chemotherapy following their secondary diagnosis had no 
impact in their survival (Table 3). 
We identified 5 patients with secondary bladder 
neoplasms of ovarian origin with a median age of 65 (53–74). 
One patient was diagnosed following an episode of frank 
haematuria requiring hospitalisation and 1 patient had 
acutely presented with abdominal pain. The remainder were 
diagnosed following radiological investigation. Two patients 
had a known primary of ovarian carcinoma diagnosed within 
Table 3 Survival variables for the primary malignancies which produced statistical significance (P<0.05). Breast, Lymphoma, Renal and Gastric 
cancers however produced ZERO statistical significant for any variable
Primary 





















of a bladder 
secondary 
Prostate 0.0013 0.0012 0.004 – – 0.12
Colorectal 0.16 0.045 – 0.03 0.013 0.24
Ovarian 0.54 – – 0.75 – 0.00002
Cervical 0.62 – – 0.043 – –
Table 2 The distribution of the primary foci of metastatic tumour’s to the bladder and their survival
Primary disease Age at diagnosis Gender M:F Tumour histology Biopsy/TURBT Overall survival 
(days)
Prostate 74 (56–90) – Adenocarcinoma All 446
Colorectal 60 (40–75) 6:3 Adenocarcinoma All 403
Ovarian 65 (53–74) – Mucinous papillary 
carcinoma
All 369
Cervical 60 (49–71) – Squamous cell 
carcinoma
All 148
Breast 65 (61–68) – Ductal carcinoma All 241
Lymphoma 80 (78–82) 1:2 Diffuse large B cell 
lymphoma
All 145
Renal 72 (59–85) 1:1 Clear cell 
adenocarcinoma
All 854
Gastric 56 (54–59) 1:1 Intestinal 
adenocarcinoma
All 66
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the last 10 years. Serous papillary carcinoma was seen in 4 
patients and 1 patient had a mucinous papillary carcinoma. 
The median time from primary to secondary diagnosis 
was 111 days (143–411). All bladder biopsy’s or TURBT 
specimens exhibited carcinoma infiltrating the muscularis 
propria. Immunohistochemistry analysis demonstrated 
positivity for CK7, WT-1 and Ca-125.The median survival 
for our patients with ovarian primary was 369 days (Table 2). 
Our results demonstrate that the most significant survival 
advantage came when patients received chemotherapy 
following diagnosis of a bladder secondary neoplasm 
(P=0.0002). Days from primary to secondary diagnosis and 
patients undergoing surgery at initial diagnosis of ovarian 
cancer did not improve survival (Table 3). 
There were 4 patients with cervical origin of secondary 
bladder neoplasms with a median age of 60 (49–71), the 
primary histology being squamous cell carcinoma. One 
patient presented with haematuria, the rest were identified 
radiologically. Two patients had been diagnosed with cervical 
cancer within the last 10 years. The median time from 
primary to secondary diagnosis was 141 days (241–324). 
All specimens exhibited carcinoma infiltrating the 
muscularis propria. Immunohistochemistry analysis of the 
bladder specimens displayed positivity for CK5, 7 and P63 
and negativity for CK20 confirming the cervical origin of 
the tumours. The median survival for patients with cervical 
cancer was 148 days (Table 2). Our results demonstrate 
that patients receiving surgery at initial diagnosis had an 
improved overall survival (P=0.043). Fewer days from 
primary to secondary diagnosis did not have a statistically 
significant effect on survival (Table 3). 
We identified 3 patients with secondary bladder 
neoplasms of breast origin (invasive ductal carcinoma) with 
a median age of 65 (61–68). All patients presented with 
urinary symptoms (haematuria and urinary retention). 
The median time from primary to secondary diagnosis was 
1,211 days (481–1,869). Immunohistochemistry analysis 
demonstrated positivity for CK7, CK8/18, ER, PR and 
CEA and a high proliferation rate of Ki67. The median 
survival for our patients was 241 days (Table 2). 
3 patients were shown to have a secondary bladder 
neoplasm of lymphocytic origin (diffuse large B cell 
lymphoma) with a median age of 80 (78–82). All three 
patients presented with urinary symptoms (recurrent UTI 
and haematuria) and had a prior diagnosis of lymphoma. 
The median time from primary to secondary diagnosis was 
368 days (146–431). The infiltrating cells were positive 
for CD45, CD20 and bcl-2 throughout. A high ki-67 
proliferative marker was also noted in all specimens. The 
median survival for our patients was 145 days (Table 2). 
We identified 2 patients with secondary bladder tumours 
of renal origin (clear cell carcinoma) with a median age 
72 (59–85). One patient presented following a routine 
surveillance scan whilst the other patient had presented 
with a 3-month history of haematuria. Both patients had a 
prior nephrectomy. One patient had an existing diagnosis 
of G3 pT1 bladder cancer. The median time from primary 
to secondary diagnosis was 2,306 days (744–3,868). Both 
specimens demonstrated a tumour immunoprofile which 
was positive for CK7, P53, AMACR63 and CEA. The 
median survival for our patients was 854 days (Table 2).
There were 2 patients with a histological diagnosis of 
secondary bladder neoplasm of gastric origin with a median 
age of 56 (54–59), Histology demonstrated an intestinal 
type adenocarcinoma of the stomach. Both patients 
presented acutely, with severe abdominal pain, and bilateral 
hydronephrosis. Neither patient had a previous history of 
malignancy however their presentation was a consequence 
of widespread metastasis. The specimens demonstrated a 
well differentiated tubular adenocarcinoma. The median 
survival for our patients was 66 days (Table 2).
Discussion
To our knowledge this is  the first comprehensive 
retrospective study of clinical profile of secondary 
neoplasms to the bladder. Previously reported studies (Bates, 
Abrams, Morichetti, Melicow, Sheehan, Xiao, Ganem) 
(2-3,5-7,10,15), have been a combination of clinical and 
autopsy cases, with primary focus being the pathological 
characteristic of the tumours, and sparse evidence of clinical 
outcomes. Although the age at presentation of bladder 
cancer is 65–70, secondary metastasis of the bladder is seen 
at 68 in men and 64 years in women, as seen in our study (16). 
Amongst our cohort, prostate cancer has been the 
highest contributor to secondary bladder neoplasms and 
prognosis of these patients has been better as oppose to 
other primaries. This could also primarily reflect current 
treatment outcomes in prostate cancer (17).
The longest duration between diagnosis of primary 
cancer and metastases was in patients with prostate and 
breast cancer, and shortest in cervical and ovarian cancer. In 
previously published series of secondary bladder cancer, the 
highest incidence was of colorectal cancer in both sexes, and 
the second most common were gynecological malignancies 
in women and prostate cancer in men (18). 
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When comparing the different sites of primary cancers, 
renal cell carcinoma appears to be the site with the longest 
survival data as compared to the others (854 days), followed 
by prostate (446 days). Furthermore, we found that other 
sites with a survival more than 365 days were colorectal and 
ovarian cancers. 
An important finding in this study is the predilection 
of histological subtype of various primary sites and their 
survival as compared to the published data. Invasive ductal 
cancer is the chief histologic subtype in breast primary, with 
a median age of 65, and average survival of 241 days, which 
is in contrast to the published data of metastatic breast 
cancer (900 days) (19). The histologic subtype in renal, 
gastric, cervical, prostate and colorectal were in keeping 
with the typical common subtype of tumours seen in these 
cancers. 
In patients with ovarian cancer as the primary, the 
papillary histology was seen in 80% of the tumours, with 
the remaining subtype being mucinous papillary carcinoma. 
Survival in our patients with ovarian cancer was 12 months 
in contrast to stage 4 ovarian cancer with a survival of 
33.6 months (20,21). This illustrates the poorer outcomes 
in bladder metastasis. The prognoses of metastasis to the 
bladder, depends upon the type of primary, rather than the 
extent of the metastases. 
There are no standard guidelines, to manage patients 
with secondary bladder cancer, however TURBT is an 
appropriate procedure, as it not only provides us with 
diagnostic information, but it is also useful for palliation 
in advanced disease. Due to the available therapeutic 
options an accurate diagnosis is essential for the optimal 
management. In samples with atypical histology, further 
analysis is advisable through immunohistochemistry to 
confirm tumour origin. Any patients with new urinary 
symptoms need to be worked up in order to exclude any 
bladder lesions (22). 
Our major findings were illustrated through examining 
prognostic variables which had an impact on survival. 
Length of time between primary and secondary disease was 
significant in prostate cancer. Those undergoing surgery 
prior to their secondary diagnosis showed a statistically 
significant improvement in survival for colorectal and 
cervical cancer. Those receiving treatment after a secondary 
diagnosis demonstrated statistical significance in survival for 
colorectal (surgery), prostate (radiotherapy and hormonal 
therapy) and ovarian cancer (chemotherapy). Breast, 
lymphoma renal and gastric cancers however produced 
zero statistical significant for any variable. This is due to 
the number of observations (patients) being fewer than 
the number of variables in question. More data points are 
required to get any form of correlation. 
This study does have its limitations. This was a 
retrospective, single centre study. The rarity of this 
diagnosis leads to a small sample size which limits its 
statistical power and makes it difficult to extrapolate 
these results. The retrospective nature of this study also 
introduces bias. We must also consider that in our breast, 
lymphoma, renal and gastric groups, limited numbers 
prevented statistically significant results. We would advocate 
a multicentre study with a larger cohort in order to be 
better equipped to recommend management. Our results 
and conclusions will be limited to patients with secondary 
neoplasms of the bladder and further research into other 
secondary malignancies will be important to provide 
comparisons. 
Conclusions
The most common secondary neoplasms of bladder are 
prostate, colorectal, and of ovarian origin. Outcomes of 
metastatic cancer to the bladder depend on a variety of 
factors including location of the primary foci, grade, number 
and location of the metastatic lesions. With the availability 
of newer immunotherapeutic options and targeted therapies 
in solid tumours, it is essential to obtain tissue diagnosis 
from bladder tumours. Radical surgery (cystectomy) is not 
advisable, as it will increase morbidity and has a limited role 
in advanced disease. There is some survival benefit in well 
selected patients receiving treatment following a diagnosis 
of a bladder secondary. With life expectancy in metastatic 
bladder cancer less than a year, and survival in secondary 
malignancies of bladder more than a year, histological, 
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Supplementary
Appendix 1 Complete patient management and individual survival for patients with secondary neoplasms of the bladder from each primary malignancy
Prostate
Treatment at initial diagnosis of Prostate Cancer Treatment following diagnosis of bladder secondary neoplasm 
Patient













Radiotherapy Other Survival (Days)
1 0 1 Direct Bone, Lymph n/a n/a n/a n/a - Docetaxel (3 cycles) 21 Gy in three 
fractions 
ADT 654
2 4748 3 Direct Bone, Lymph 
nodes
n/a n/a 70 Gy in 35 
fractions
ADT - - - - 97
3 1693 1 Direct Bone, Lymph Open Prostatectomy n/a 70 Gy in 35 
fractions 
n/a - Docetaxel (6 cycles) 21 Gy in three 
fractions
ADT 1250
4 0 3 Direct Lymph, bone n/a n/a n/a n/a - - - ADT 259
5 0 2 Direct Bone, Lymph, Lung n/a n/a n/a n/a - - 21 Gy in three 
fractions
ADT 632
6 0 4 Direct Lymph n/a n/a n/a n/a - - - ADT 77
7 4388 2 Direct Lymph n/a n/a 70 Gy in 35 
fractions
n/a - Docetexal (6 cycles) - ADT 1489
8 0 2 Direct Lymph, bone n/a n/a n/a n/a - Docetexal (6 cycles) 21 Gy in three 
fractions
ADT 1407
9 0 1 Direct Lymph, bone n/a n/a n/a n/a - Docetexal (6 cycles) 21 Gy in three 
fractions
ADT 961
10 0 3 Direct Lymph n/a n/a n/a n/a - - - ADT 210
11 948 3 Direct Lymph, Bone, Lung n/a n/a 70 Gy in 35 
fractions
ADT - - - ADT 154
12 0 3 Direct Lymph, bone, liver n/a n/a n/a n/a - - - ADT 114
Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary prostate malignancy. ADT- androgen deprivation therapy.
Colorectal
Treatment at initial diagnosis of Colorectal Cancer Treatment following diagnosis of bladder secondary neoplasm 
Patient










Radiotherapy Other Surgery Chemotherapy (Number of cycles) Radiotherapy Other
Survival 
(Days)
1 1342 2 Distant Lymph, liver Extended 
Hemicolectomy
6 cycles adjuvant 
Oxaliplatin/Capecitabine 
- - 6 cycles FOLFIRI and Bevacizumab 3 
cycles (Cetuximab 1 cycle TAS-102 
- - 260
2 0 1 Direct Lymph, lung, liver, 
peritoneum 
- - - - Anterior resection+ TAH 
+ BSO + cystectomy 
FOLFIRI 25 Gy in 5 
fractions
bevacizumab 1286 
3 0 1 Direct Lymph, liver - - - - Radical cysto-
prostatectomy + 
hartmans
6 cycles Raltitraxed + Oxaliplatin - - 627
4 0 3 Direct Lymph, lung, liver, 
bone
- - - - - - - - 99
5 2979 3 Distant Lymph, lung Anterior Resection - 25 Gy in 5 
fractions
- - Raltitraxed, Oxaliplatin 6 cycles - - 403
6 321 2 Direct lymph Hemicolectomy FOLFOX 6 cycles - - - FOLFIRI 4 cycles - - 341
7 62 2 Direct Lymph, liver Hemicolectomy Oxaliplatin 6 cycles - - - fluorouracil/folinic acid 6 cycles - - 543
8 81 2 Direct Lymph, peritnium, 
liver 
anterior resection + 





- - 6 cycles FOLFIRI and Bevacizumab 20 Gy 5 
fractions
- 720
9 0 3 Direct Lymph - - - - - - - - 84
Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary colorectal malignancy. FOLFOX- Folinic acid/Fluorouracil (5FU)/Oxaliplatin, FOLFIRI- Folinic acid/Fluorouracil (5FU)/Irinotecan, TAS-102- Trifluridine/tipiracil. TAH +BSO- Total 
Abdominal Hysterectomy + Bilateral Salpingo-oophorectomy.
Ovarian
Treatment at initial diagnosis of Ovarian Cancer Treatment following diagnosis of bladder secondary neoplasm 
Patient











Chemotherapy (Number of 
cycles)
Radiotherapy Other Survival (Days)
1 0 2 Direct Lymph, peritoneum, 
liver
- - - - TAH+ BSO+ Omentectomy 
+ partial cystectomy
 paclitaxel and carboplatin + 
gemcitabine 4 cycles
- - 695
2 143 1 Distant Lymph, peritoneum TAH + BSO Carboplatin+ paclitaxel 
+ Avastin 6 cycles
- - - - - - 410
3 0 2 Direct Lymph, peritonium - - - - - Avastin and paclitaxel 1 cycle - - 369
4 0 2 Direct Lymph, lung - - - - - - - - 127
5 411 3 Distant Lymph, lungs, liver TAH + BSO carboplatin and 
docetaxel 6 cycles 
- - - - - - 81
Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary ovarian malignancy. TAH +BSO- Total Abdominal Hysterectomy + Bilateral Salpingo-oophorectomy.
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Cervical
Treatment at initial diagnosis of Cervical Cancer Treatment following diagnosis of bladder secondary neoplasm 
Patient










Radiotherapy Other Surgery Chemotherapy (Number of cycles) Radiotherapy Other Survival (Days)
1 241 3 Direct Lymph, liver - Cisplatin 2 cycles 20 Gy 5 fractions - - - - - 125
2 324 2 Direct Lymph, rectum TAH + BSO Cisplatin 6 cycles 20 Gy 5 fractions - Cisplatin +paclitaxel 3 cycle 20 Gy 5 fractions 236
3 0 3 Direct Lymph, rectum - - - - - Cisplatin not tolerated then 
gemcitabine 1 cycle
20 Gy 5 fractions 162
4 0 3 Direct Lymph, rectum, Liver - - - - - - - 134
Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary cervical malignancy. TAH +BSO- Total Abdominal Hysterectomy + Bilateral Salpingo-oophorectomy.
Breast
Treatment at initial diagnosis of Breast Cancer Treatment following diagnosis of bladder secondary neoplasm 
Patient





Other Mets/ extent of disease Surgery





Radiotherapy Other Survival (Days)
1 1869 1 Distant Bone, Lymph, Liver, Brain, Lung Mastectomy FEC+ paclitaxel 6 cycles Radiotherapy trastuzumab - docetaxel - Pertuzumab+ Trastuzumab+ 241
2 1211 2 Distant Lymph, Bone, Liver Mastectomy FEC + Docetaxel 6 cycles Radiotherapy - - - - Anastrazole 162
3 481 2 Distant Lymph, Liver, Lung Mastectomy FEC + Docetaxel 6 cycles Radiotherapy Trastuzumab - Paclitaxel - Trastuzumab 369
Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary breast malignancy. FEC- 5 fluorouracil (5FU) Epirubicin, Cyclophosphamide.
Lymphoma
Treatment at initial diagnosis of Lymphoma Treatment following diagnosis of bladder secondary neoplasm 
Patient
Time between primary diagnosis and 
secondary (days)
PS Method of spread






Chemotherapy (Number of 
cycles)
Radiotherapy Other Survival (Days)
1 146 3 hematopoietic Spleen, Liver - - - - - - - - 98
2 431 2 hematopoietic Bone marrow, Lung - - - - - - - - 145
3 368 2 hematopoietic Lung, Liver - CHOP + Methotrexate - - - - - - 278
Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary lymphoma. CHOP- Cyclophosphamide, Doxorubicin (Adriamycin), Vincristine (Oncovin), Prednisolone.
Renal
Treatment at initial diagnosis of Renal Cell Carcinoma Treatment following diagnosis of bladder secondary neoplasm 
Patient
Time between primary diagnosis and 
secondary (days)
PS Method of spread








Radiotherapy Other Survival (Days)
1 744 2 Distant Liver, Lung Radical Nephrectomy - - - - - - -TKI 326
2 3868 0 Distant Lung Radical Nephrectomy - - - - - - TKI 1383
Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary renal malignancy. TKI- Tyrosine Kinase Inhibitor.
Gastric
Treatment at initial diagnosis of Gastric Cancer Treatment following diagnosis of bladder secondary neoplasm 
Patient Time between primary diagnosis and 
secondary (days)
PS Method of spread Other Mets/extent of 
disease
Surgery Chemotherapy (Number of 
cycles)
Radiotherapy Other Surgery Chemotherapy (Number 
of cycles)
Radiotherapy Other Survival (Days)
1 0 2 Distant Liver, Bone - - - - - epirubicin, cisplatin, and 
fluorouracil 1 cycle
- - 98
2 0 3 Distant Liver, Peritonium, Lung - - - - - - - - 31
Complete patient management and individual survival for patients with secondary neoplasms of the bladder from a primary gastric malignancy.
